cyrilzakka/clinical-trials huggingface dataset:
Facial Prediction Technology for Edentulous Patients

According to data from the World Health Organization, approximately 160 million people worldwide are edentulous. The incidence increases with age, and the proportion of edentulous patients is higher in the population aged 60 and above. Loss of teeth or edentulism can affect facial appearance, causing people to feel self-conscious and loss confidence in social situations, and even lead to psychological illnesses. Therefore, edentulous patients not only pay close attention to the recovery of oral function but also attach great importance to facial contour improvement. For a long time, due to technological limitations, clinicians have been unable to depict the changes in facial contour after implant placement for patients before surgery. However, with the development of artificial intelligence technology, deep learning-based methods for predicting soft tissue facial deformation have made this mission a possibility. This study established a multi-modal dataset for edentulous patients before and after implant restoration to lay the foundation for predicting facial contour changes after implant treatment. A graph generative adversarial network based on multi-modal data was proposed to achieve fast and high-precision facial contour prediction. To address the common challenges of slow computation and excessive computational resource consumption in current triangular mesh deformation simulation methods, this project innovatively proposed a graph generative adversarial network that uses multi-modal data and incorporates self-attention mechanisms to achieve fast and high-precision facial contour prediction for edentulous patients after implant restoration.


Eligibility Criteria:
Inclusion Criteria:

* Patients with complete edentulism,
* aged 50 years or above,
* in good physical health,

Exclusion Criteria:

* patients who refuse to participate in the study，
* patients who cannot undergo facial scanning.
Effects of Tucatinib on Cardiac Repolarization in Healthy Participants

This study is looking at how the study drug, tucatinib, affects the heart. Tucatinib is being studied as a possible treatment for breast cancer. This study will recruit healthy volunteers. There are 3 parts in the study. Each volunteer will be in all 3 parts. One part will be to take the study drug, the second part will be to take a placebo (pill with no medicine), and the third part will be to take moxifloxacin. The volunteers will only know what part of the study they are in when they take moxifloxacin. For the study drug and placebo parts, volunteers will take 2 pills by mouth for 5 days. For the moxifloxacin part, volunteers will take 1 pill by mouth for 1 day.

This study will evaluate the effects of a steady state therapeutic dose of tucatinib on QTcF (QT interval corrected for heart rate using Fridericia's method) in healthy individuals. In this design, study treatment will be dosed in 3 sequential treatment periods:

Treatment A: Oral doses of 300mg tucatinib for 5 days

Treatment B: Oral doses of matching placebo for tucatinib for 5 days

Treatment C: A single oral dose of 400 mg of moxifloxacin

Patients will be randomized based on 2-Williams-square design to 1 of 6 treatment sequences to maintain the study blind for tucatinib and placebo.

Eligibility Criteria:
Inclusion Criteria:

* Good health, determined by medical history, physical examination, 12-lead ECG, vital signs measurements, or clinical laboratory evaluations
* Body mass index (BMI) between 18 and 32 kg/m\^2
* Body weight between 50 and 100 kg
* Female subjects must be of non-childbearing potential
* Male subjects must agree to use contraception or be surgically sterile for at least 90 days

Exclusion Criteria:

* Significant history of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder
* Any condition affecting drug absorption
* History of hypersensitivity or allergy to any drug compound, food, or other substance
* Single 12-lead ECG demonstrating QTcF \>450 msec for males or \>470 msec for females, or history/evidence of long QT syndrome
* History of alcoholism or drug/chemical abuse within 2 years
* Use of prescription products within 30 days prior to check in
* Use of nonprescription products within 14 days prior to check in, including vitamins, minerals, and herbal supplements
* Use of tobacco- or nicotine-containing products within 3 months prior to check in
A Study of Tomato Products and Disease Risk

The purpose of this research study is to test whether certain compounds in tomatoes will help reduce factors in the subject's blood associated with disease risk. The investigators want to know if the tomato-associated compounds will lower or improve the status of these factors, like cholesterol and inflammation. In this research study, the subject will be asked to consume high fat test meals on two separate occasions. The investigators want to see how the subject's body responds to a standard high fat meal, one meal with tomato products and one meal without tomato products. The investigators will measure the subject's blood throughout the study period to determine if consumption of tomato products reduces factors in their blood associated with disease risk.

This study will take three weeks at most, and require one initial screening visit lasting approximately 45 minutes and two study visits each lasting approximately 6 - 8 hours. The investigators are looking for healthy, non-smoking male and female volunteers between the ages of 18 - 65, with no medical history of diabetics, heart, lung, kidney, stomach, or liver disease.

The initial screening visit will determine subject' eligibility through height, weight and waist circumference measurements, blood glucose (finger prick) test and a fasting screening blood draw. There will be no compensation for the screening visit, other than transportation costs.

If subject qualify, subject will continue to the two study visits. Each visit will require subject to have blood drawn several times during subject' study visit (total amount of blood equal to approximately 1 ½ tablespoons). To make this process more tolerable, a registered nurse will place a catheter (similar to what happens when you give blood) into subject's vein for ease in drawing blood. After the catheter placement and the first blood draw, subject will be asked to eat the test meal (tomato or non-tomato meal) and then subject will continue to have blood taken at specific time points for the next 6 hours. The investigators will also do an ultrasound on subject's arm to measure blood flow both before eating and midway through the 6 - hour study visit. The investigators will ask that subject not consume tomatoes or tomato products during the course of the study and record all food and beverages consumed on certain days.

Eligibility Criteria:
Inclusion Criteria:

* Male and female
* Between ages of 18-65
* BMI between 19 and 24 and hsCRP \< 1mg/L
* BMI between 25 and 35 and hsCRP \> 2.5mg/L
* No clinical evidence of cardiovascular, respiratory, renal, GI or hepatic disease

Exclusion Criteria:

* Pregnant and/or lactating
* allergies or intolerances to foods consumed in the study
* fasting blood glucose \> 110mg/dL
* taking OTC antioxidant supplements, prescription meds that may interfere with study endpoints
* unusual dietary habits
* actively trying to lose or gain weight
* addicted to drugs or alcohol
* medically documented psychiatric or neurological disturbances
* smoker (past smoker allowed if cessation \> 2 years)
Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload

This study will evaluate the safety and efficacy of deferasirox in transfusion dependent Myelodysplastic Syndrome, Beta-thalassaemia major patients with chronic iron overload


Eligibility Criteria:
Inclusion criteria:

* In- or outpatients with myelodysplasia / with risk of low or intermedier-1 according to the International Prognostic Scoring System (IPSS) confirmed by bone marrow evaluation within 3 month/ or beta thalassaemia major patients, who have chronic iron overload, as a consequence of frequent blood transfusion
* Serum ferritin\> 1800 µg/L
* Age: 18-80 years
* men and women
* Chronic iron overload caused by at least 30 units and maximum 100 units of blood of packed red blood cells
* Deferoxamin therapy is contraindicated or inadequate or unable to use in the recommended dose due to intolerability or other reason
* Eastern Cooperative Oncology Group (ECOG) performance status score between 0-2
* written informed consent

Exclusion criteria:

* beta thalassaemia minor,
* haemosiderosis caused by other than chronic transfusional iron overload,
* patients with impaired renal function (Creatinin clearance\< 60 ml/ min),
* pregnancy,
* lactation,
* patient of childbearing potential unwilling to use contraceptive precautions
* known hypersensitivity to deferasirox or any ingredients,
* impaired hepatic function (SGOT,SGPT 5x above UNL).
* Patients severely ill due to underlying disease progression or other severe concomitant disease.
* Patients with poor prognosis of karyotype
* patients with malabsorption caused by inflammatory bowel disease, gastrectomy, pancreatitis or other medical condition
* History of nephrotic syndrome
* Significant proteinuria
* Patients with a previous history of clinically relevant ocular toxicity related to iron chelation
* Patients with positive test to HIV

Other protocol-defined inclusion/exclusion criteria may apply
EEG Guidance of Anesthesia (ENGAGES-CANADA)

This study examines the potential link between deep levels of anesthesia and delirium.

ENGAGES CANADA is a parallel study to the ENGAGES study which has been published in JAMA, DOI:10.1001/jama.2019.5161. Due to the difference in practice models and types of anesthesia principles, ENGAGES CANADA is an important study. Delirium is a relatively common postoperative complication in the geriatric population, affecting 20% to 70% of surgical patients over the age of 60. Delirium manifests as confusion, inattention and the inability to think logically, and may affect the patient's postoperative healing and rehabilitation. It is associated with persistent cognitive decline, longer hospital stay, increased incidence of injurious falls, and increased mortality. Patients undergoing major cardiac surgery are at a significant risk of postoperative delirium. To date, there is no proven method to prevent postoperative delirium in this patient population and often delirious events remain unrecognized. Randomized controlled studies in diverse surgical patient populations suggest that intraoperative electroencephalography (EEG) guidance during general anesthesia may decrease postoperative delirium and adverse postoperative outcomes. Patients who experience postoperative delirium report persistently decreased quality of life and it is a risk factor for incident psychiatric disorders and psychotropic medication use. One potential key mechanism in the relationship between delirium and incident psychiatric illness may be the experience of dissociation (disturbed awareness, impaired memory, or altered perceptions) in the perioperative period in those who are delirious. The co-occurrence of psychiatric illness and delirium can put older adults at greater risk of negative long terms effect such as functional decline. This study will compare the effectiveness of two anesthetic protocols in reducing postoperative delirium and postoperative health-related quality of life in a high risk population.We expect that EEG-guided anesthetic management of patients during their operative procedure will result in improved health-related outcomes, specifically decreased incidence of postoperative delirium and improved postoperative mental and physical health outcomes.

Eligibility Criteria:
Inclusion Criteria:

1. Adults 60 years or older;
2. Competent to provide informed consent;
3. Undergoing elective cardiac surgery requiring cardiopulmonary bypass.

Exclusion Criteria:

1. Unable to provide informed consent;
2. Preoperative delirium;
3. Unable to participate adequately in delirium screening including those who are blind, deaf, illiterate or not fluent English or French;
4. History of intraoperative awareness
A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)

This is a 3-period study. Periods 1 and 2 will evaluate the effects of multiple doses of laropiprant on the antiplatelet effects of clopidogrel and aspirin administered in combination in participants with primary hypercholesterolemia or mixed dyslipidemia. Period 3 will be open-label and will evaluate single dose pharmacokinetics of nicotinic acid and laropiprant components of Tredaptive.


Eligibility Criteria:
Inclusion Criteria:

* Participant has primary hypercholesterolemia or mixed dyslipidemia (high cholesterol)
* Participant is a non-smoker

Exclusion Criteria:

* Participant has a history of chronic seizures
* Participant has a history of cancer
* Participant has a history of stomach or intestinal ulcers or any history of GI bleeding
* Participant has had major surgery, donated blood or participated in another investigational study in the past 4 weeks
Effect of Knee Bracing on Improving Pain & Disability

The overall purpose of the proposed pilot study is to establish the feasibility of conducting a clinical trial by evaluating the preliminary effects of 8 weeks of knee bracing on physiological measures of self-reported pain and disability, physical performance, physical activity, as well as femoral cartilage deformation in individuals with medial compartment knee osteoarthritis (OA). The investigators will recruit 36 symptomatic knee OA patients for the pilot study. The investigators will evaluate a class of braces (two different models will be used) designed to correct genu varum. The purpose of the study is to evaluate changes in these novel outcomes following the use of a class of braces used to reduce medial tibiofemoral compartment compression used for 8 weeks. This pilot study will inform a larger future trial to determine the efficacy of bracing on decreasing disability and disease progression in patients with knee osteoarthritis.


Eligibility Criteria:
Inclusion Criteria:

Participants must:

* have a physician diagnosis of knee OA in the medial compartment and exhibit symptomatic knee OA, which the investigators will define as a normalized, person based, Western Ontario and McMaster Universities Arthritis Index (WOMAC) function subscale score \> 31 (out of 100 points, indicating most dysfunction).
* have had a knee radiograph taken within the previous 6 months.
* be between the ages of 40 and 75 years old will be included.

Exclusion Criteria:

Participants will be excluded if they have:

* been diagnosed with a cardiovascular condition restricting exercise;
* had a corticosteroid or hyaluronic acid injection in the involved knee in the previous 2 weeks;
* a pacemaker;
* a neurodegenerative condition;
* rheumatoid arthritis;
* cancer;
* neural sensory dysfunction over the knee;
* a BMI over 35;
* history of lower extremity orthopaedic surgery in the past year;
* a history of a traumatic knee injury in the past 6 months;
* any history of a total knee arthroplasty in either extremity; or
* a diagnosed, non-reconstructed knee ligament tear.
* the need of an assistive device to walk.

The investigators will also exclude pregnant women, as well as women who are trying to get pregnant or plan to get pregnant during the study.
Transcriptomic Evaluation of Endometrial Receptivity

The purpose of this study is to comprehensively evaluate the transcriptomic signal of the endometrium before, during, and after the window of receptivity.

Phase 1 will aim to define a normal endometrial transcriptomic signature in healthy controls without infertility. Phase 2 will elucidate endometrial transcriptomic expression in patients with diagnoses of infertility unrelated to endometrial factor. Findings from this phase will be compared to the results of phase 1.

Eligibility Criteria:
Phase 1:

Major Inclusion: The following are major inclusion criteria:

1. Regular menstrual cycles
2. Age 18-50
3. Normal baseline ultrasound
4. No intrauterine procedures in prior 90 days

Exclusions: The following are exclusion criteria:

1. Any contraindications to undergoing estrogen stimulation of the endometrium

   1. Current smoking status
   2. Multiple risk factors for arterial cardiovascular disease (smoking, diabetes, and hypertension)
   3. Hypertension (systolic ≥140 mmHg or diastolic ≥90 mmHg)
   4. Venous thromboembolism (current or history of)
   5. Known thrombogenic mutations
   6. Known ischemic heart disease
   7. History of stroke
   8. Complicated valvular heart disease (pulmonary hypertension, risk for atrial fibrillation, history of subacute bacterial endocarditis)
   9. Systemic lupus erythematosus (positive or unknown antiphospholipid antibodies)
   10. Migraine with aura at any age
   11. Breast cancer
   12. Cirrhosis
   13. Hepatocellular adenoma or malignant hepatoma
2. History of infertility diagnosis
3. History of undiagnosed abnormal uterine bleeding.
4. Allergic reaction to any medication used for the preparatory cycle
5. Known pregnancy or delivery within the past 6 months
6. Breastfeeding
7. Obesity \>35 kg/m2

Phase 2

Major Inclusion: The following are major inclusion criteria:

1. Age 18-50
2. Diagnosis of infertility with low endometrial risk
3. No intrauterine procedures in prior 90 days

Exclusions: In addition to the exclusion criteria for phase 1, patients deemed to have an elevated endometrial risk will also be excluded. This would include the following:

1. Recurrent implantation failure
2. Failed transfer with a euploid blastocyst
3. History of Asherman's or abnormal endometrial function
4. History of endometriosis
Greater Occipital Nerve (GON) Block Effectivity in the Treatment of Chronic Migraine: 6 Months Follow up

This study evaluates effectiveness of greater occipital nerve blocks with bupivacaine compared to placebo in chronic migraine patients.

The greater occipital nerve (GON), which derives most of its fibers from the C2 dorsal root, is the primary sensory nerve of the occipital region. The response to GON blockade was not simply dependent on the direct local anesthetic effect of the injection . The mechanism of action might have been via changes in brain nociceptive pathways. Another possible explanation for these findings is, therefore, that GON injections initiated diffuse noxious inhibitory controls, independent of anesthetic effect . Neurophysiological and clinical data suggest there is a functional connection between the sensory occipital segments and the trigeminal nociceptive system in humans.

Eligibility Criteria:
Inclusion Criteria:

* Chronic migraine headache according to International Headache Society Classification Criteria
* Patients who are not using any prophylacting agent

Exclusion Criteria:

* patients given similar treatments before
* pregnant women
* hereditary diseases causing bleeding
* patients who have intracranial tumor or operation in posterior fossa
* allergic reactions to local anesthetics.
COVID-19 Infection and Multiple Myeloma

Collect in an observational study the outcomes of COVID19 infection in MM patients across Europe.

Coronavirus Disease 2019 (COVID-19), caused by a novel coronavirus (SARS-CoV-2), is a highly contagious disease that appeared in Wuhan, Hubei province of China in December 2019. It has now spread to multiple countries through infected persons travelling mainly by air. Most of the infected patients have mild symptoms including fever, fatigue and cough. But in severe cases, patients can progress rapidly and develop the acute respiratory distress syndrome, septic shock, metabolic acidosis and coagulopathy including a disseminated intravascular coagulation (DIC).

Multiple myeloma (MM) is a mature B-cell malignancy largely affecting the older patient with a median age at presentation of 70 years. The general performance status (PS) and the presence of comorbidity can identify a group of patients with poor tolerance to treatment, as well as risks of both bacterial and viral infection. MM patients have benefited significantly from therapeutic developments, however, the host response biology of the older person, coupled with a distinct disease biology overlay induces immune dysfunction. For example, the impact of aging on the human immune system is well documented. In MM it has long-since been understood that there is a spectrum of immune dysregulation, an important host factor considered in the "Hallmarks of cancer" theory. In addition, the delivery of anti-MM therapy includes immune modulating agents such as steroids, proteasome inhibitors and CD38-directed therapy though not all immune modulation is necessarily detrimental.

As such, myeloma patients are considered a higher risk in the current pandemic with SARS-COVID19. However, it is not clear whether this is actually the case, and the risk may not be different to population in general. Equally it may be sub-groups of patients who are at risk e.g. on treatment versus stable response (plateau), frailty. AS such, this proposal aims to collect in an observational study, the outcomes of COVID19 infection in MM patients across Europe.

Eligibility Criteria:
Inclusion Criteria:

* Multiple Myeloma patients
* COVID-19 infection
Fatty Acid Biomarkers of Carbohydrate Intake

The overall aim is to investigate if circulating fatty acids and lipids are influenced by alterations in carbohydrate amount and quality.

In this isocaloric clinical cross-over trial, the investigators aim to investigate if circulating fatty acids and lipids are influenced by alterations in carbohydrate amount and quality. The investigators intend to evaluate if changes in carbohydrate quantity and quality (including sugar) influence circulating even-chain saturated fatty acids or if fatty acid-derived indices of desaturation and de novo lipogenesis are more sensitive biomarkers of carbohydrate intake. By performing untargeted lipidomic analyses, the investigators aim to search for novel lipid biomarkers of carbohydrate quantity and quality. The investigators also want to evaluate the influence of moderate alterations of carbohydrate and sugar intake on lipoproteins, insulin sensitivity, inflammatory proteins.

Eligibility Criteria:
Inclusion Criteria:

* BMI 20-38

Exclusion Criteria:

* abnormal lab tests (assessed by screening and judged by a physician), diabetes, cardiovascular, kidney, liver or malignant disease, and weight-loss (±3kg) the preceding 3 months of screening. Extreme diets, i.e. very-low carbohydrate diets, intermittent fasting, vegan diets or allergic to gluten
Orthostatic Hypotension in Hypertensive Patient Hospitalized in Internal Medicine

The two scientific societies FADOI and SIIA have decided to start a collaborative study protocol that, through the application of a simple and homogeneous method to diagnose orthostatic hypotension, aims to estimate prevalence, conditions associates and outcomes in a cohort of patients admitted to Internal Medicine Departments and with known or newly diagnosed arterial hypertension.

The IP-OP study, is an observational, multicenter, prospective, national study that provides for the involvement of 34 Operating Units of Internal Medicine, and the recording of data relating to 1000 hospitalized adults.

The clinical data of all consecutive patients diagnosed with arterial hypertension hospitalized in Internal Medicine and able to take the erect station will be collected.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years
* Presence of arterial hypertension (known or discovered at hospitalization)
* Signature of Informed Consent

Exclusion Criteria:

* Patients unable to take the standing station for a few minutes